Hohzawa K, Shibuya M, Yuasa R
Jpn J Antibiot. 1983 Oct;36(10):2921-4.
Micronomicin sulfate (MCR) is a new aminoglycoside antibiotic, and its antibacterial spectrum is similar to that of gentamicin (GM). According to the animal test, MCR has less ototoxicity than other aminoglycoside antibiotics such as GM. To check its clinical ototoxicity, MCR was given intramuscularly to 20 patients at dose of 120--240 mg/day, respectively for 2--8 days, and audiometry was carried out before and after administration of MCR. No evident change was detected between the preadministration hearing levels and the postadministration hearing levels. These data suggest that MCR is sufficiently safe in ototoxicity within dose of 120 mg/day for 4 days.
硫酸小诺米星（MCR）是一种新型氨基糖苷类抗生素，其抗菌谱与庆大霉素（GM）相似。根据动物试验，MCR的耳毒性比GM等其他氨基糖苷类抗生素小。为了检测其临床耳毒性，对20例患者分别给予每日120 - 240mg剂量的MCR肌肉注射，持续2 - 8天，并在MCR给药前后进行听力测定。给药前和给药后的听力水平之间未检测到明显变化。这些数据表明，在每日120mg剂量、持续4天的情况下，MCR在耳毒性方面足够安全。
